Archive

Medical Category: Hematology and Oncology

ANNEXA-4: Andexanet Alfa and Factor Xa Inhibitors

Background: Over the past few years we have seen a surge in the use of oral Factor Xa inhibitors (apixaban, rivaroxaban etc) for anticoagulation.  The reason for this is the ease of use, standard dosing with no levels to check and …

Read More
Hematology and Oncology

D-Dimer in Pregnancy: Limiting Radiation with Pre-test Probability

Background: Pulmonary embolism is the leading cause of death in pregnancy and the puerperium – accounting for nearly 20% of maternal deaths in the United States – making rapid and accurate diagnosis critically important for emergency physicians, OB/GYNs, and all …

Read More
Hematology and OncologyObstetrics and Gynecology

LMWH in Cancer-Related VTE (CLOT Study)

Background: Venous thromboembolism (VTE) occurs frequently in patient with cancer. Treatment in this group entails a number of challenges including a higher rate of thrombosis recurrence and a higher risk of bleeding. Standard therapy in 2018 for both symptomatic and …

Read More
Hematology and Oncology

Edoxaban in Cancer-Associated VTE

Background: Venous thromboembolism (VTE) occurs frequently in patient with cancer. Treatment in this group entails a number of challenges including a higher rate of thrombosis recurrence and a higher risk of bleeding. Standard therapy at this time for both symptomatic …

Read More
Hematology and Oncology

Rebellion in EM 2018 – DOAC Reversal by Scott Wieters, MD

The 1stannual Rebellion in EM Clinical Conference took place in San Antonio, TX on May 11th– 13th, 2018.  If you missed out in 2018, the Rebellion is coming back June 28th – 30th, 2019.  Stay up to date as we plan …

Read More
Hematology and Oncology

Sponsored